Skip to main
MIRM

MIRM Stock Forecast & Price Target

MIRM Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Mirum Pharmaceuticals Inc. has experienced significant revenue growth, with LIVMARLI sales reaching $88.1 million in Q2 2025, reflecting an impressive 87% increase year-over-year. The company has adjusted its 2025 revenue guidance upward to a range of $490 million to $510 million, demonstrating robust commercial momentum fueled by the rising adoption of LIVMARLI in treating Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). Additionally, the total revenues for Q2 2025 amounted to $127.8 million, marking a 64% year-over-year growth, which reinforces a positive outlook for the company's financial performance.

Bears say

Mirum Pharmaceuticals faces significant commercial risks due to its dependence on method of use and formulation patent coverage for maralixibat, lacking robust composition of matter patent protection. The company's revenue is in an early growth phase, and unexpected competition or slower sales growth could hinder its ability to achieve profitability. Compounding these challenges, the presence of multiple competing ASBT inhibitors in development, along with the company's recent financial losses from the termination of a revenue interest purchase agreement, further contributes to a negative outlook on the stock.

MIRM has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mirum Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mirum Pharmaceuticals Inc (MIRM) Forecast

Analysts have given MIRM a Buy based on their latest research and market trends.

According to 12 analysts, MIRM has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $91.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $91.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mirum Pharmaceuticals Inc (MIRM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.